Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The HANDS Act requires Medicare, Medicaid, and TRICARE to cover naloxone and other opioid overdose reversal drugs at no cost to patients when distributed by hospitals, emergency departments, and ambulatory surgical centers. Specifically, healthcare providers would furnish these drugs to patients identified as at-risk for opioid overdose at the time of discharge or when leaving the facility, along with administration instructions. The coverage takes effect January 1, 2026, and eliminates all cost-sharing—including deductibles and copayments—for eligible beneficiaries across all three programs. The bill also directs federal health agencies to issue guidance within one year to help hospitals bill for these drugs and to assist state licensing boards in removing regulatory barriers to their distribution. No provider is required to furnish the drugs, and the legislation does not specify new funding but instead amends existing insurance programs to cover this preventive treatment.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.